➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
AstraZeneca
Colorcon
Moodys
McKesson

Last Updated: August 11, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,974,770

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,974,770 protect, and when does it expire?

Patent 9,974,770 protects TOSYMRA and is included in one NDA.

This patent has sixteen patent family members in thirteen countries.

Summary for Patent: 9,974,770
Title:Formulations comprising triptan compounds
Abstract: The invention provides a pharmaceutical composition for intranasal administration comprising a salt of sumatriptan or a physiologically acceptable solvate thereof, an alkyl glycoside or saccharide alkyl ester and optionally at least one pharmaceutically acceptable excipient, wherein the said composition provides T.sub.max value of less than 30 minutes upon said administration. Other aspects and embodiments are contemplated and described. The invention also provides a pharmaceutical composition for intranasal administration comprising a triptan, a pharmaceutically acceptable vehicle and a mucosal permeation enhancer, wherein upon said administration said composition provides a T.sub.max substantially equivalent to subcutaneous administration of said triptan. Other aspects and embodiments are contemplated and described.
Inventor(s): Gandhi; Rajesh (Sagar, IN), Manikonda; Sreekanth (Visakhapatnam, IN), Jana; Arun (Panna, IN), Kunte; Sameer Shrinivas (Mumbai, IN)
Assignee: DR. REDDY'S LABORATORIES LTD. (Hyderabad, IN)
Application Number:15/434,814
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 9,974,770

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Upsher Smith Labs TOSYMRA sumatriptan SPRAY;NASAL 210884-001 Jan 25, 2019 RX Yes Yes   Start Trial   Start Trial Y ACUTE TREATMENT OF MIGRAINE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Baxter
McKinsey
Colorcon
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.